Treatments & Services

Available Trials

Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.

If you are interested in learning more about our research program, please call the VOA Research Department in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach


Breast Cancer Research

  • USO 19009

    USO 19009: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)

    Available at 3 locations

  • USO 18232

    USO 18232: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)

    Available at 1 location

  • USO 17-188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 5 locations

  • USO 18042

    USO 18042: A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-Negative Breast Cancer (C3441020)

    Available at 5 locations

  • USO 17082

    USO 17082: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (I3Y-MC-JPCF) monarchE

    Available at 3 locations

  • USO 17027

    A Multi-Centre, Open-Label, Randomized Clinical Trial Comparing The Efficacy And Safety Of The Antibody-Drug Conjugate SYD985 To Physician's Choice In Patients With HER2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer

    Available at 1 location

  • USO 17009

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

    Available at 5 locations

  • Alliance A011502 (ABC Trial)

    A Randomized Phase III Double Blinded Placebo-Controlled Trial Of Aspirin As Adjuvant Therapy For Node-Positive, HER2 Negative Breast Cancer

    Available at 6 locations

Genitourinary Cancer Research

  • USO 18283

    USO 18283: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

    Available at 3 locations

  • USO 16052

    USO 16052: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma - Bristol-Myers Squibb CA209-274

    Available at 2 locations

  • USO 18095

    A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

    Available at 5 locations

  • JANSSEN 56021927PCR2032

    JANSSEN 56021927PCR2032: An Open-label, Multicenter, Phase Ib Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer

    Available at 1 location

  • USO 17165

    USO 17165: Phase 1b/2 Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations (42756493BLC2002)

    Available at 1 location

  • USO 17146

    USO 17146: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (1205-201)

    Available at 1 location

  • Duke Panther Pro00075097

    Duke Panther Pro00075097: Prospective Study of Apalutamide and Abiraterone Acetate In Chemo Therapy Naïve Men with mCRPC Stratified by Race (Pro00075097)

    Available at 2 locations

  • USO 16237

    A Multicenter, Open-Label Phase 2 Study Of Rucaparib In Patients With Metastatic Castration-Resistant Prostate Cancer Associated With Homologous Recombination Deficiency TRITON2: CO-338-052

    Available at 2 locations

  • USO 17005

    A Single-Arm, Open-Label, Multicenter Study Of Enfortumab Vedotin (ASG-22CE) For Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy - SGN22E-001

    Available at 5 locations

  • MDV3800-06

    A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

    Available at 2 locations

  • USO 16251

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

    Available at 2 locations

  • USO 15228

    A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

    Available at 2 locations

GYN Cancer Research

  • USO 18232

    USO 18232: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)

    Available at 1 location

  • USO 17182

    USO 17182: Clovis A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ClovisCO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA)

    Available at 3 locations

Lung Cancer Research

  • USO 17140

    USO 17140: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (GO40241)

    Available at 4 locations

  • USO 18234

    USO 18234: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer (AB928CSP0004)

    Available at 1 location

Solid Tumors Research

  • USO 18109

    A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (20170758)

    Available at 5 locations

  • LOXO-EXT-17005

    LOXO-EXT-17005: Phase 1/2 Study Of The TRK Inhibitor LOXO-195 In Adult And Pediatric Subjects With Previously Treated NTRK Fusion Cancers

    Available at 1 location

  • USO 18057

    USO 18057: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors (CA030-001)

    Available at 1 location

  • Ignyta (RXDX 101-02)

    An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    Available at 1 location

  • USO 15239

    A Phase I, Open-Label, Multiple-Ascending Dose Trial To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of MSB0011359C In Subjects With Metastatic Or Locally Advanced Solid Tumors And Expansion To Selected Indications

    Available at 1 location